Document:

EXECUTION COPY

                                    EXHIBIT A
                       CCC INFORMATION SERVICES GROUP INC.
                                SUMMARY OF TERMS

ISSUER:                  CCC Information Services Group Inc. (the "Company")

PURCHASER:               Capricorn Investors III, L.P., and/or one or more
                         affiliates (the "Purchaser").

SECURITIES:              Trust preferred stock (the "Trust Preferred Stock") of
                         a new business trust owned by the Company which will
                         own $15,000,000 of senior subordinated notes of the
                         Company that will be subordinated to the Company's bank
                         debt, and warrants to acquire 1,200,000 shares of the
                         Company's common stock, (the "Warrants", and together
                         with the Trust Preferred Stock, the "Securities").

PURCHASE PRICE:          $15,000,000 in the aggregate for the Securities.

ADDITIONAL INVESTORS:    At the Company's election, the principal amount of the
                         Trust Preferred Stock to be sold may be increased to
                         $65,000,000 and the number of warrants may be increased
                         proportionately to 5,200,000 to accommodate Condor, and
                         any other additional investors ("Additional
                         Investors"). Additional Investors will not be
                         accommodated if the increase in the Securities would
                         require a vote of the shareholders of the Company or if
                         the increase would in any way cause a delay in the
                         closing of the Transaction. Additionally, in the event
                         the Condor transaction is not consummated in full, and
                         the Company determines to sell Securities to other
                         Additional Investors, Capricorn will be entitled, for
                         15 days from receipt of written notice of such
                         determination, to designate one (1) or more of its
                         limited partners as such Additional Investors before
                         the Company will be entitled to designate another
                         person as an Additional Investor (it being acknowledged
                         and agreed, that Capricorn's limited partner or
                         partners, as the case may be, may, in its or their, as
                         the case may be, sole discretion, elect to purchase up
                         to all of the Securities allocated by the Company for
                         Additional Investors). Any Additional Investors (other
                         than limited partners and general partners of
                         Capricorn) must be reasonably acceptable to Capricorn
                         and the Company's Board of Directors.

                         The Purchaser will be entitled to the benefit of any
                         terms and conditions, including without limitation,
                         economic terms, contained in the definitive
                         documentation of a transaction consummated with any of
                         Condor or the Additional Investors within 9 months of
                         the closing date of the transaction with the Purchaser,
                         that are more favorable to the Purchaser, provided,
                         that such modification to the Purchaser's terms and
                         conditions shall not apply to such terms and conditions
                         that are relative to the size of the investment of the
                         Additional Investors (e.g. number of board members,
                         number of demand or other registrations, etc.).

                                       4
<PAGE>
                                                                  EXECUTION COPY

GENERAL                  Definitive Documentation for the purchase of the Trust
                         Preferred Stock will contain customary representations,
                         warranties and closing conditions, but will not include
                         ongoing indemnification obligations after the closing.

                         In the event that the Company does not, within 9 months
                         from the closing of the Transaction, either (i)
                         consummate the Surf transaction, or (ii) consummate the
                         Condor transaction, the Company will, at Capricorn's
                         request, use its best efforts to obtain alternative
                         financing, provided that, in such event, Capricorn and
                         its affiliates will be given the opportunity to
                         participate in such alternative financing on a pro-rata
                         basis relative to the shareholdings of the Company's
                         shareholders who decide to participate in such
                         alternative financing. In addition, Capricorn and its
                         affiliates will be entitled to exchange their
                         Securities (valued at stated value plus accrued but
                         unpaid dividends), in lieu of cash, for any equity or
                         equity equivalent securities that may be issued in any
                         such alternative financing.

USE OF PROCEEDS:         Working Capital and General Corporate Purposes.

TERMS OF TRUST
PREFERRED STOCK:

    RANKING:             The Trust Preferred Stock and the related senior
                         subordinated notes of the Company held by the trust
                         (the "Notes") will effectively rank senior to all other
                         capital stock of the Company. The Notes will be
                         unsecured, will be subordinated to the Company's bank
                         facility, and will rank pari passu with the Company's
                         other debt for borrowed money, except any such debt
                         that is expressly subordinated to the Notes. The Notes
                         from the Company to the business trust will contain
                         customary debt provisions (including, but not limited
                         to events of default and acceleration provisions). The
                         Notes will not be guaranteed by any subsidiary or other
                         affiliate of the Company.

    DIVIDENDS:           The dividend rate of the Trust Preferred Stock will be
                         (i) 9% per annum, payable in cash or in kind at the
                         Company's option, for the first three years from the
                         closing of the issuance of the Securities (the
                         "Closing") and (ii) 11% per annum, payable in cash,
                         thereafter. Dividends will be cumulative, whether or
                         not declared, and will be payable, either in PIK or
                         cash as applicable, on a quarterly basis.

    MATURITY:            The Trust Preferred Stock will be mandatorily
                         redeemable at its stated value plus accrued but unpaid
                         dividends 5 years following the Closing.

    OPTIONAL             All or any portion of the outstanding Trust Preferred
    REDEMPTION:          Stock may be called for redemption at the option of the
                         Company at any time after the 3rd anniversary of the
                         Closing. Such redemption must be on at least 30
                         business days' prior written notice to the Purchaser.
                         The redemption price will be equal to the stated value
                         thereof plus accrued but unpaid dividends.

    PROTECTIVE           While the Trust Preferred Stock is outstanding, the
    PROVISIONS:          holders of the Trust Preferred Stock, through their
                         control of the trust and the Notes, will have certain

                                       5
<PAGE>
                                                                  EXECUTION COPY

                         approval rights including, without limitation, with
                         respect to (i) restricted payments, (ii) incurrence of
                         indebtedness (subject to baskets to be negotiated and
                         with the understanding that borrowings from a revolving
                         credit facility as approved by the Purchaser do not
                         constitute an incurrence of indebtedness), (iii)
                         creation of liens, (iv) imposition of dividends and
                         other payment restriction affecting restricted
                         subsidiaries, and (v) transactions with affiliates. For
                         purposes of the debt incurrence provision referred to
                         above, the Company will be able to incur debt if, after
                         giving effect to such incurrence of debt (and treating
                         the Trust Preferred Stock for this purpose as debt),
                         the Company's pro forma leverage ratio (for the
                         trailing 12 months and after taking into account such
                         factors, including cost savings to be realized in any
                         merger or acquisition transaction, as shall be agreed
                         to by the parties) of debt to EBITDA is equal to or
                         less than 3.5 to 1.1 The pro forma leverage ratio shall
                         be calculated to exclude negative EBITDA from the
                         DriveLogic and International businesses in the amounts
                         of (i) the actual negative EBITDA incurred during the
                         first three quarters of fiscal year 2000, (ii) up to
                         $15 million in negative EBITDA incurred during the
                         fourth quarter of fiscal year 2000, not including
                         one-time items as disclosed in the Company's financial
                         statements for the fourth quarter of fiscal year 2000,
                         and (iii) up to $25 million in aggregate negative
                         EBITDA incurred during fiscal year 2001 and the first
                         two quarters of fiscal year 2002.

    CHANGE OF            Upon a change of control of the Company, the Purchaser
    CONTROL:             will have the right, in its sole discretion, to require
                         the Company to repurchase the Trust Preferred Stock at
                         a price equal to 100% of the stated value thereof plus
                         accrued but unpaid dividends.

WARRANTS:

    EXERCISE PRICE:      The exercise price of the Warrants shall be ten dollars
                         ($10.00) per share, subject to customary antidilution
                         adjustments, as described below. Cashless exercise will
                         be permitted. Additionally, Purchaser will be entitled
                         to tender Trust Preferred Stock, valued at stated value
                         plus accrued but unpaid dividends, to satisfy the
                         payment owed in connection with the exercise of the
                         Warrants.

    TERM:                The Warrants will have a term of 5 years from the date
                         of the original issuance. The Warrants may be exercised
                         at any time.

    ANTI-DILUTION        The Warrants will have the benefit of customary
    PROVISIONS:          anti-dilution protection. Without limiting the
                         foregoing, the holders of Warrants will be protected by
                         means of an anti-dilution provision which adjusts the
                         exercise price on a weighted average basis upon any
                         issuance by the Company of common stock (or securities
                         convertible into common stock) at a price lower than
                         the market price of the common stock at the time of
                         such issuance.

-------------------
(1) EBITDA will be determined, to the extent applicable, by reference to
    Regulation S-X as reasonably interpreted by the Company's Chief Financial
    Officer.

                                       6
<PAGE>
                                                                  EXECUTION COPY

    EXTRAORDINARY        The holders of Warrants will get the benefit of
    DISTRIBUTIONS ON     extraordinary distributions made on shares of common
    COMMON STOCK:        stock while the Warrants are outstanding.

   TRANSFER:             The Trust Preferred Stock and the Warrants will not be
                         transferable until the third anniversary of the closing
                         date of the Transaction and thereafter will be freely
                         transferable subject only to securities law limitations
                         on transferability; provided, that prior to such third
                         anniversary, Purchaser may transfer the Trust Preferred
                         Stock and Warrants to its general partners, limited
                         partners or affiliates so long as (i) such entities
                         agree to be bound by the same terms and conditions, and
                         (ii) such transfer would not cause the Company to
                         register the Trust Preferred Stock or the Warrants (a
                         "Permitted Transfer"). The shares of common stock
                         underlying the Warrants will be freely transferable at
                         any time (regardless of whether the Trust Preferred
                         Stock is being transferred) subject only to securities
                         law limitations.

VOTING RIGHTS:           The holders of the Securities shall vote with the
                         holders of common stock, on a basis as if the Warrants
                         had been exercised.

BOARD REPRESENTATION:    The board of directors of the Company shall have seven
                         (7) members, but may be increased up to eleven (11)
                         members. Currently, Herbert S. "Pug" Winokur and Dudley
                         C. Mecum, affiliates of the Purchaser, have been
                         elected to the board of directors of the Company. In
                         the future, the Purchaser will have the right to have
                         one (1) designee elected to the board of directors of
                         the Company, pursuant to its ownership of the Warrants
                         and Trust Preferred Stock (i) for as long as no
                         Warrants or common stock underlying the Warrants are
                         sold or transferred by the Purchaser (other than
                         Permitted Transfers and exercises of the Warrants) or
                         (ii) upon the sale or transfer of any Warrants or
                         common stock underlying the Warrants so long as the
                         Purchaser, Capricorn Investors II, L.P., their
                         respective limited partners and general partners, and
                         affiliates (collectively "Purchaser Affiliates") retain
                         5% or more of the Company's then-outstanding common
                         stock (determined after giving effect to the exercise
                         of any of the unexercised Warrants). If as a result of
                         the sale or transfer of the Warrants or common stock,
                         the Purchaser, Purchaser Affiliates and affiliates own
                         less than 5% of the common stock (determined after
                         giving effect to the exercise of any of the unexercised
                         Warrants), the Purchaser will not be entitled to select
                         any directors of the Company merely as a result of the
                         Transaction. Notwithstanding anything to the contrary
                         contained herein, any nominee for the Company's board
                         of directors designated by the Purchaser shall be
                         consented to, in advance, by the Company's board of
                         directors, which consent shall not be unreasonably
                         withheld. Additionally, so long as Purchaser is
                         entitled to a Board seat in accordance with the
                         provisions described above, the Purchaser designee
                         shall be a member of the Company's compensation and
                         nominating committee, and the chairman of such
                         committee shall be reasonably acceptable to such
                         designee.

                                       7
<PAGE>

                                                                  EXECUTION COPY

 REGISTRATION RIGHTS     The Company and the Purchaser will enter into a
 AGREEMENT:              registration rights agreement. Such agreement will
                         provide for the following:

     DEMAND              Holders of the Warrant Shares will have the right to
     REGISTRATION        require the Company to effect up to one underwritten
     RIGHTS:             registration and two shelf registrations of such shares
                         on Form S-3, provided that such shares in any such
                         registration have an aggregate offering price in excess
                         of $5,000,000. Expenses will be paid by the Company.

                         If, for any reason, the Company is not eligible to
                         register securities on Form S-3, the holders of Warrant
                         Shares will have the right to require the Company to
                         effect up to an aggregate of one underwritten
                         registration and one shelf registration on Form S-1.
                         Expenses will be paid by the Company. The Company will
                         have the right to preempt any notice of a demand
                         registration. If the Company does not preempt a demand
                         request, the stockholder making such demand will have
                         first priority in any cut-back with respect to such
                         demand registration.

                         Demand registrations will be subject to the following
                         limits: (i) no demand may be made within the first year
                         following the closing of the Transaction; (ii) no
                         demand may be made within 180 days from the Company's
                         most recent registration; and (iii) registration rights
                         will be subject to customary blackout provisions.

    PIGGY-BACK           Holders of Warrant Shares will have unlimited piggyback
    REGISTRATION         registration rights, subject to customary pro rata
    RIGHTS:              underwriter cut-backs. Expenses will be paid by the
                         Company.

NO SUPERIOR              Without the consent of the holders of a majority of the
REGISTRATION RIGHTS:     Warrants and Warrant Shares, the Company will not grant
                         registration rights to any other person that are
                         superior in any respect to those granted to such
                         holders, other than with respect to securities issued
                         to customers in an aggregate amount not to exceed
                         500,000 shares.

EXPENSE REIMBURSEMENT    Upon the consummation of the Transaction, the Company
                         will reimburse the Purchaser for all of its
                         out-of-pocket documented expenses up to a cap of
                         $200,000 (including but not limited to legal fees and
                         expenses, accounting fees and expenses and fees and
                         expenses of consultants).

NASDAQ:                  The Company and its attorneys will communicate with
                         Nasdaq to ensure that the Transaction as structured
                         will not result in any shareholder approval
                         requirement. Purchaser's attorneys will be permitted to
                         participate in this process.

TAX CONSIDERATIONS:      The transactions contemplated hereby will be structured
                         so as to ensure that the tax treatment to each of the
                         parties will be as favorable as possible.

                                       8HAIGHT-ASHBURY FREE
                                 MEDICAL CLINIC

MEDICAL SECTION               DRUG DETOXIFICATION,          WOMEN'S NEEDS
558 Clayton Street            REHABILITATION AND AFTER      1698 Haight Street
San Francisco, CA             CARE PROJECT                  San Francisco, CA
94117                         529 Clayton Street            94117
(415) 431-1714                San Francisco, CA 94117       (415) 621-1003
                              (415) 621-2014/621-2015

                              EFFICACY OF BUFFERED
                               ASCORBATE COMPOUND
                                  (BAC) IN THE
                               DETOXIFICATION AND
                              AFTERCARE OF CLIENTS
                             INVOLVED IN OPIATE AND
                                 STIMULANT ABUSE

               Former Director:                   John Newmeyer, Ph.D.
               Project Director:                   Darryl Inaba, Ph.D.
               Medical Director:                  David E. Smith, M.D.
               Research:                        Gary E. Waldorf, Ph.D.
                                              Stephen A. Levine, Ph.D.

                         PRODUCT DESIGN RESEARCH SURVEY

                            DEVELOPED AND FUNDED BY

                             ALLERGY RESEARCH GROUP

<PAGE>

                                     SUMMARY

     We conclude that for outpatient use, the Buffered Ascorbate Compound (BAC*)
was valuable as an adjunct agent to the existing medical program used at the
clinic in reducing apparent withdrawal symptoms. The efficacy of this technique
needs more controlled and extended studies to more fully understand the effects
of BAC in treatment of patients withdrawing from regular drug abuse.

     In general, reduced withdrawal symptoms were reported by most clients with
those in aftercare reporting a remarkable 90% loss of craving for the specific
substance they were abusing. The longer the client used the BAC, the more
benefit they derived from it. Those who missed taking the compound felt a
significant letdown and resumed the use of the BAC. There was a very low dropout
rate (less than 1%), and only one person reported any side effects which were of
minor consequences (bowel incontinence) from use of the BAC.

     A number of variables has no significant effects on the effectiveness of
the BAC in relieving withdrawal symptoms. These included sex, race, age,
initiation day (for use of BAC in treatment cycle), and frequency and amount of
BAC used. The educational level achieved by the patient was a significant
variable, as was the marital status, and the status of their treatment,
(preliminary treatment or aftercare) in determining the effectiveness of BAC in
relieving withdrawal symptoms. Those with higher educational background derived
more benefit than those with less formal education. Those who were single
benefited more than those who were married. The reason for the significance of
these variables is not clear.

       OBJECTIVES OF THE PROJECT

      In view of the feasibility of detoxifying opiate and stimulant abusers
using a non-pharmacological approach, and because of the simplicity of the
technique used, it was suggested that the BAC could be given orally as an
out-client treatment modality. The first pilot study of the application of BAC
to outpatient treatment regime in detoxification of opiate and stimulant
addiction was therefore established in June 1983 at the Haight-Ashbury Free
Medical Clinic's Detox and Aftercare Unit in San Francisco, California.

     The objectives of the pilot program were to examine whether:

1. Clients would use the BAC for detoxification, and it is would contribute to
the existing program in discouraging subsequent abuse.

2. If the BAC by itself, and as an adjunct to other medication given at the
clinic, would alleviate withdrawal symptoms and stop further craving for these
substances.

                                   METHODOLOGY

SUBJECTS

     Males and females, 18 and older, who were clients at the Haight-Ashbury
Free Medical Clinic's Detox and Aftercare project were eligible for the testing
program. All clients were aware that they were part of a study. All clients were
instructed as to what it was that they were taking and how to take the BAC.
Demographic and background data were used to permit an understanding of persons
opting to use BAC. Furthermore, a questionnaire was used on a daily basis to
evaluate the effect of BAC in relieving detoxification symptoms and preventing
further use after detoxing.

PROCEDURE

     Efficacy was measured in terms of how effective the Buffered Ascorbate
compound was in relieving withdrawal symptoms and preventing further use after
detoxing, while the client was on the program. This was done by daily evaluation
in the pharmacy of the clinic. A scale of 1 to 10 (scored by the patient) was
used to evaluate effectiveness of BAC in relieving acute withdrawal symptoms.
This information was reported by the clients on a daily basis.

TREATMENT REGIMEN

     All clients using BAC were shown how to use it and were given a two or
three day supply. Refills were available at any time when the clinic was open.
Any anticipated side effects of the BAC were explained to the client by
participating staff members.

                                        2

<PAGE>

VARIABLES ASSOCIATED WITH EFFECTIVENESS:

      The major focus of this project was to determine if the BAC could be used
as an effective treatment modality for opiate and stimulant users on an
outpatient basis. Twelve variables were considered in regards to the possible
effectiveness of the BAC.

     These variables included sex, race, relationship status, formal education
completed, type of drug previously abused (opiates or stimulants), frequency of
use of BAC, starting day in which the clients began to use the BAC in
detoxification or aftercare, and variations in effectiveness of BAC in symptom
relief, as certain of the patients resumed some frequency of drug abuse. The
reported quantity of BAC used was evaluated in relationship to the reported
effectiveness in relieving withdrawal symptoms.

NUMBERS ENTERING TREATMENT

      The study was conducted at HAFMC DAU from July 1, 1983, through August 31,
1983. There were 61 persons in the study: 21 women and 40 men.

SUMMARY OF DATA

      One third of the clients (20) reported that 70% or more of acute
withdrawal symptoms were relieved when taking BAC in the active detox phase of
the program. One half (30) reported at least 60% relief. One fifth (12) reported
symptom relief of 30% or less.

1. Sex was not a significant factor in regards to the effectiveness of BAC in
detoxification and in preventing opiate and stimulant abuse. (Chi sq. = .0161)

2. Age appeared not to be a significant factor in regards to the value of BAC in
aiding detoxification. The population of clients were divided into two age
groups: those born before and those born after January 1950. Thus, according to
this finding, the classification of clients into an older and younger group, had
no significance in relationship to value of BAC. (Chi sq. = 1.0662)

3. Race classification (whites and nonwhites) was not a significant variable.
(Chi sq. = .4535)

4. Those who were single derived more benefit from use of BAC than those who
were married, had been divorced or separated, or reconciled. (Chi sq. = 29.05)

5. Clients who had finished one year of college did far better than clients who
had not. The median relief of symptoms reported by those who had been to one
year of college was 70%. (Chi sq. = 2.84)

6. Those holding part or full time jobs were compared to those who were
unemployed. In this manner employment status was not a significant variable in
regards to reported benefit from use of BAC. (Chi sq. = 1.40)

7. Those whose primary drug use was that of opiates was compared to clients
whose primary drug use was of stimulants. This classification was not
significant in regards to the reported benefits from use of BAC.

8. Date of first use of BAC was compared. Those who began use during the first
10 days were compared to those who began use of BAC during the second 10 days of
the program. According to this classification, those starting during the first
half of the program reported benefits that were not significantly different than
those who started during the second part of the program.

9. Frequency of previous drug abuse was determined. Those who had used drugs
twice or more daily reported benefits from the use of BAC that were not
significantly different than those who used drugs less than twice daily.

10. Active-detox clients were compared with clients in aftercare in regards to
reported benefits gotten from BAC. It was found that the aftercare clients
reported significantly greater benefit from use of BAC (Chi sq. = 2.71). The
median symptom relief reported by the aftercare group was 90% relief of
symptoms.

11. The dosage of BAC was considered in relation to the reported benefit. When
considering the dosage range used by the clients at a single treatment (range
from 1/2 to 1-1/2 teaspoons of BAC in water or juice) the dosage was found to be
insignificant in regards to the benefits reported by the clients (Chi sq. =
1.0006). This finding suggests that clients could benefit substantially from
relatively small dose of BAC.

                                   CONCLUSION

     This pilot study suggests that a significant benefit was obtained from the
clients participating

                                        3

<PAGE>

in the study when using BAC in their detox and aftercare programs. This benefit
was seen in rapid relief of acute withdrawal symptoms, as well as discouraging
resumption of drug abuse. We believe that these findings are very encouraging
and that further study of the use of BAC in drug treatment programs is
warranted. We believe that it would be advisable to conduct more detailed
studies in which controlled use of the BAC is seriously evaluated in regards to
other important variables, such as specific relief of withdrawal symptoms,
psychological effects, dosage protocols, urine and saliva pH variations, as well
as other physiological parameters which might give us some indications to some
more exact functions of BAC in drug-abuse treatment programs.

      In-depth evaluation of the mechanisms of action of BAC in providing acute
relief from withdrawal symptoms would inevitably yield data which was relevant
to the underlying causes and consequences of the biochemical enigma (addiction)
which is epidemic in our population.

      There are many advantages of the BAC for use in treatment of drug abusers.
It is easily and economically administered, and patients need not be
hospitalized during treatment. It can be carried with the client, Counseling is
feasible throughout the treatment program as clients remain alert and physical
health appears to be enhanced. No serious side effects have been noted.

      Practitioners report no advantages associated with administration of BAC
for treatment of substance abuse, assuming proper technique and procedure.
However, the following should be noted:

1. When using oral solutions over a long period of time, care should be taken to
allow 15 seconds before drinking. This will allow the buffering effect of the
mineral salts to eliminate the acidity of the ascorbic acid. There have been
some reports indicating that continued long term use of oral ascorbate solutions
will do damage to the tooth enamel (Cathcart, 1983). Any acidic drink (even
Coca-Cola) can lead to tooth enamel damage due to acidification of the enamel.

2. Patients with Sickle Cell Anemia or Glucose-6-phosphate enzyme deficiencies
should only take gram quantities of ascorbate compounds under a doctor's
supervision. Ascorbates may be less well tolerated where there exists
abnormalities in the function of the hexose monophosphate shunt or certain
enzyme deficiencies exit, ie., glutathione reductase, glutathione peroxidase, or
glutathione synthetase (Stanbury et al. 1983).

                              SELECTED BIBLIOGRAPHY

     Bourne, PG. Non-pharmacological Approaches to the Treatment of Drug Abuse.
Am. J. Chinese Med 3:235244, 1975.

     Buler, Henry GMD. Food is Your Best Medicine. New York:Random House, 1966.
pp. 6078.

     Cathcart R. Presentation at: Orthomolecular Medical Society Meeting October
1982/Los Angeles.

     Gilman A & Goodman L. The Pharmacological Basis of Therapeutics. New
York:MacMillan Publishing. Sixth Edition, 1980.

     Pauling, Linus. Vitamin C and the Common Cold. San Francisco:Freeman, 1976.
pp. 3060.

     Rosenberg, Harold MD & Feldzman AN. A Doctor's Book of Vitamin Therapy. New
York:Putnam, 1974. pp 48-60.

     Stanbury JB, Wyngaarden J, & Fredrickson D. The Metabolic Basis of
Inherited Diseases. McGraw Hill. Fifth Edition, 1983.

     Stone, Irwin. Healing Factor: Vitamin C Against Disease. New York:Grosset &
Dunlap, 1972. pp. 80-87.

     Williams RJ. Nutrition Against Disease: Environmental Prevention. New
York:Bantum, 1971. pp. 20-25.

     Valentine F & Saunders. Journal of Orthomolecular Psychiatry, Vol. 7:No.4,
1978. pp. 264-270.

ACKNOWLEDGMENTS

     Special thanks to Stephen A. Levine, Ph.D., for providing free Buffered C
formula; to Greg Hayner, Ph.D., and Andy Rice, R.N., for collecting data; to
Darryl Inaba, Ph.D., for allowing the project; to John Newmeyer for technical
help; and Beth for typing the original report.

   Scottsdale Scientific, Inc.
   Allergy Research Group/Nutricology, Inc.
   30806 Santana St., Hayward, CA 94544
   info.- 800.545.9960 o Order - 800.752.4274
   Fax-51O.487.8682, info@nutricology.com

                                        4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}]]